Literature DB >> 22568412

Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy.

Ching-Wei D Tzeng1, Jason B Fleming, Jeffrey E Lee, Xuemei Wang, Peter W T Pisters, Jean-Nicolas Vauthey, Gauri Varadhachary, Robert A Wolff, Matthew H G Katz.   

Abstract

BACKGROUND: Following potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield.
METHODS: All patients who underwent pancreaticoduodenectomy for PAC at this institution during 1998-2008 were identified. Patients with asymptomatic recurrence were compared with those with symptomatic recurrence. Factors associated with survival following the detection of recurrence were compared.
RESULTS: A total of 216 of 327 (66.1%) resected patients developed recurrence. Asymptomatic recurrence was detected in 118 (54.6%) patients. Symptomatic recurrence was associated with multifocal disease or carcinomatosis, poor performance status and less frequent subsequent therapy. Median time to recurrence did not differ between groups, but survival after detection was shorter in symptomatic patients (5.1 months vs. 13.0 months; P < 0.001). Treatment was administered more frequently to asymptomatic patients (91.2% vs. 61.4%; P < 0.001). At recurrence, a preserved performance status score of ≤ 1, further therapy, low CA 19-9, and an isolated site of recurrence were independently associated with longer post-recurrence survival (P < 0.001).
CONCLUSIONS: Overall, 54.6% of cases of recurrent PAC were detected prior to the onset of symptoms using a standardized clinical and radiographic surveillance strategy. Although this retrospective analysis limits definitive conclusions associating this strategy with survival, these results suggest the need for further studies of postoperative surveillance.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22568412      PMCID: PMC3384860          DOI: 10.1111/j.1477-2574.2012.00445.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  26 in total

1.  Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy.

Authors:  H Ueno; S Okada; T Okusaka; M Ikeda
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

2.  Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.

Authors:  Matthew H G Katz; Huamin Wang; Aparna Balachandran; Priya Bhosale; Christopher H Crane; Xuemei Wang; Peter W T Pisters; Jeffrey E Lee; Jean-Nicolas Vauthey; Eddie K Abdalla; Robert Wolff; James Abbruzzese; Gauri Varadhachary; Xavier Chopin-Laly; Chusilp Charnsangavej; Jason B Fleming
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

3.  Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial.

Authors:  Francisco Rodríguez-Moranta; Joan Saló; Angels Arcusa; Jaume Boadas; Virgínia Piñol; Xavier Bessa; Eduard Batiste-Alentorn; Antonio M Lacy; Salvadora Delgado; Joan Maurel; Josep M Piqué; Antoni Castells
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

4.  Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer?

Authors:  Joseph J Bennett; Mithat Gonen; Michael D'Angelica; David P Jaques; Murray F Brennan; Daniel G Coit
Journal:  J Am Coll Surg       Date:  2005-10       Impact factor: 6.113

5.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

6.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

Review 7.  Follow-up strategies for women treated for early breast cancer.

Authors:  M P Rojas; E Telaro; A Russo; I Moschetti; L Coe; R Fossati; D Palli; Turco M del Roselli; A Liberati
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

8.  Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.

Authors:  Sunil Krishnan; Vishal Rana; Nora A Janjan; James L Abbruzzese; Morris S Gould; Prajnan Das; Marc E Delclos; Shana Palla; Sushovan Guha; Gauri Varadhachary; Douglas B Evans; Robert A Wolff; Christopher H Crane
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

9.  Is reporting of recurrence data important in pancreatic cancer?

Authors:  Michael O Meyers; Ingrid M Meszoely; John P Hoffman; James C Watson; Eric Ross; Burton L Eisenberg
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

10.  Psychological effects of routine follow up on cancer patients after surgery.

Authors:  G M Kiebert; K Welvaart; J Kievit
Journal:  Eur J Surg       Date:  1993 Nov-Dec
View more
  24 in total

1.  Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Authors:  Ching-Wei D Tzeng; Aparna Balachandran; Mediha Ahmad; Jeffrey E Lee; Sunil Krishnan; Huamin Wang; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Peter W T Pisters; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

2.  Information needs among patients and a surveillance strategy after surgery for pancreatic and periampullary cancer.

Authors:  Knut J Labori; Caroline S Verbeke; Ivar P Gladhaug
Journal:  HPB (Oxford)       Date:  2015-03-16       Impact factor: 3.647

3.  Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Jordan M Cloyd; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Laura Prakash; Rebecca A Snyder; Gauri R Varadhachary; Robert A Wolff; Milind Javle; Rachna T Shroff; David Fogelman; Michael Overman; Huamin Wang; Anirban Maitra; Jeffrey E Lee; Jason B Fleming; Matthew H G Katz
Journal:  Cancer       Date:  2016-05-31       Impact factor: 6.860

4.  Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study.

Authors:  David L Chan; Matthew Cheung; Craig C Earle; Natalie Coburn; Nicole Mittmann; Farah Rahman; Ning Liu; Simron Singh
Journal:  J Gastrointest Cancer       Date:  2020-03

5.  The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.

Authors:  Ryan M Thomas; Mark J Truty; Michael Kim; Ya'an Kang; Ran Zhang; Deyali Chatterjee; Matthew H Katz; Jason B Fleming
Journal:  Ann Surg Oncol       Date:  2014-11-18       Impact factor: 5.344

6.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

7.  Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Authors:  Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee
Journal:  J Gastrointest Surg       Date:  2016-10-24       Impact factor: 3.452

8.  Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection.

Authors:  Laura R Prakash; Huamin Wang; Jun Zhao; Graciela M Nogueras-Gonzalez; Jordan M Cloyd; Ching-Wei D Tzeng; Michael P Kim; Jeffrey E Lee; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2019-02-28       Impact factor: 3.452

Review 9.  Intensity of follow-up after pancreatic cancer resection.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Ann Surg Oncol       Date:  2013-10-04       Impact factor: 5.344

Review 10.  The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Authors:  Eugene J Koay; William Hall; Peter C Park; Beth Erickson; Joseph M Herman
Journal:  Abdom Radiol (NY)       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.